Detalles de la búsqueda
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34953525
3.
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
Future Oncol
; 19(15): 1021-1028, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36942803
4.
Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT).
Support Care Cancer
; 31(7): 442, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402060
5.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35411939
6.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35671327
7.
Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression.
Br J Cancer
; 122(9): 1315-1323, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32157242
8.
The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies.
Epidemiology
; 31(3): 432-440, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31651660
9.
Use of bisphosphonates and other bone supportive agents in the management of prostate cancer-A UK perspective.
Int J Clin Pract
; 74(11): e13611, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32654366
10.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30355464
11.
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
BMC Cancer
; 19(1): 12, 2019 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30612558
12.
Consensus on molecular imaging and theranostics in prostate cancer.
Lancet Oncol
; 19(12): e696-e708, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30507436
13.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
; 387(10024): 1163-77, 2016 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26719232
14.
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Eur J Nucl Med Mol Imaging
; 44(4): 620-629, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770145
15.
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
Eur J Nucl Med Mol Imaging
; 44(8): 1319-1327, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28421240
16.
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
BJU Int
; 119(4): 522-529, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27256016
17.
Active surveillance for favorable-risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review.
Psychooncology
; 26(10): 1411-1421, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27862602
18.
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Lancet Oncol
; 17(9): 1306-16, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27473888
19.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 17(8): 1047-1060, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27339115
20.
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 16(16): 1605-16, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26522334